Farah, C.; Neveu, M.-A.; Yelek, C.; Bouzin, C.; Gallez, B.; Baurain, J.-F.; Mignion, L.; Jordan, B.F.
Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts. Biomedicines 2022, 10, 717.
https://doi.org/10.3390/biomedicines10030717
AMA Style
Farah C, Neveu M-A, Yelek C, Bouzin C, Gallez B, Baurain J-F, Mignion L, Jordan BF.
Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts. Biomedicines. 2022; 10(3):717.
https://doi.org/10.3390/biomedicines10030717
Chicago/Turabian Style
Farah, Chantale, Marie-Aline Neveu, Caner Yelek, Caroline Bouzin, Bernard Gallez, Jean-François Baurain, Lionel Mignion, and Bénédicte F. Jordan.
2022. "Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts" Biomedicines 10, no. 3: 717.
https://doi.org/10.3390/biomedicines10030717
APA Style
Farah, C., Neveu, M.-A., Yelek, C., Bouzin, C., Gallez, B., Baurain, J.-F., Mignion, L., & Jordan, B. F.
(2022). Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts. Biomedicines, 10(3), 717.
https://doi.org/10.3390/biomedicines10030717
